SodaStream and GlaxoSmithKline released the earnings results from their first fiscal quarters before opening bell this morning. SodaStream posted adjusted earnings of 40 cents on $91.3 million in sales for the quarter. Analysts had been expecting the beverage machine manufacturer to break even in adjusted earnings on sales of $101 million. In the same quarter last year, SodaStream posted revenue of $118.2 million and 8 cents per share in earnings.
GlaxoSmithKline reported core earnings of 17.3 pence, a 16% decline, core profits of £1.31 billion and sales of £5.6 billion, a 1% year over year increase. Analysts had been looking for £1.31 billion in core profits and sales of £5.65 billion for the quarter.
Key metrics from SodaStream’s earnings report
SodaStream’s GAAP earnings were 29 cents per share, compared to 8 cents per share last year including charges related to restructuring. Adjusted EBITDA for the quarter ros from $6.5 million last year to $7.6 million in the first quarter of 2015. The discontinuation of some products reduced sales by about $1 million.
SodaStream recorded $54.6 million in revenue from Western Europe, a decline from $62.5 million. Revenues from The Americas fell from $34.8 million to $22.8 million, while Central and Eastern Europe, the Middle East, and Africa recorded a decline from $4.9 million to $9 million in sales.
The beverage machine maker saw sales of its soda maker starter kits decline from $32.2 million last year to $27.5 million in the first quarter of 2015. Sales of consumables plunged from $83 million to $63 million, while sales of other products declined from $3 million to $0.8 million.
SodaStream said it sold 518,000 soda maker starter kits during the quarter, a decline from last year’s 604,000. The company sold 6.046 million CO2 refills, an increase from 5.82 million last year. Sales of flavors plunged to 4.922 million units from 8.405 million units last year.
Key metrics from GlaxoSmithKline’s earnings report
GlaxoSmithKline’s Vaccines pro forma sales increased 3% in the quarter, while pro forma Consumer Healthcare sales rose 8% compared to last year. Vaccines Group sales grew 10%, while Consumer Healthcare Group sales increased 24%. Total Pharmaceuticals Group sales declined 7% year over year.
Management expects revenue to increase at a compound annual growth rate in the low- to mid-single digits over the five years from 2016 to 2020. They expect sales of vaccines to grow in the mid- to high-single digits and pharmaceuticals sales to increase in the low single digits, including the introduction of the generic Advair drug.
GlaxoSmithKline expects core earnings to grow at a compound annual growth rate in the mid- to high-single digits over 2016 to 2020.